Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is a major worldwide health problem. Recent studies suggest that the gut microbiota influences NAFLD pathogenesis. Here, a murine model of high-fat diet-induced (HFD-induced) NAFLD was used, and the effects of alterations in the gut microbiota on NAFLD were determined. Mice treated with antibiotics or tempol exhibited altered bile acid composition, with a notable increase in conjugated bile acid metabolites that inhibited intestinal farnesoid X receptor (FXR) signaling. Compared with control mice, animals with intestine-specific Fxr disruption had reduced hepatic triglyceride accumulation in response to a HFD. The decrease in hepatic triglyceride accumulation was mainly due to fewer circulating ceramides, which was in part the result of lower expression of ceramide synthesis genes. The reduction of ceramide levels in the ileum and serum in tempol- or antibiotic-treated mice fed a HFD resulted in downregulation of hepatic SREBP1C and decreased de novo lipogenesis. Administration of C16:0 ceramide to antibiotic-treated mice fed a HFD reversed hepatic steatosis. These studies demonstrate that inhibition of an intestinal FXR/ceramide axis mediates gut microbiota-associated NAFLD development, linking the microbiome, nuclear receptor signaling, and NAFLD. This work suggests that inhibition of intestinal FXR is a potential therapeutic target for NAFLD treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hence, treatment with antibiotics ameliorates high-fat-diet-induced NAFLD in mice55.”
From The gut microbiome and liver cancer: mechanisms and clinical translation (2017) · cites this paper as [55]
In the citing paper
“Conversely, some data also indicate that antagonism of intestinal FXR signaling could improve metabolic parameters in murine models of NAFLD [256,257].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [257]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Bile salt biotransformations by human intestinal bacteria
Ridlon, J. M., Kang, D.-J., & Hylemon, P. B. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r500013-jlr200 · Cited by 2,829
Mechanisms underlying the resistance to diet-induced obesity in germ-free mice
Bäckhed, F., Manchester, J. K., Semenkovich, C. F., & Gordon, J. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605374104 · Cited by 2,615
Sayin, S. I., Wahlström, A., Felin, J., Jäntti, S., Marschall, H.-U., Bamberg, K., Angelin, B., Hyötyläinen, T., Orešič, M., & Bäckhed, F. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.01.003 · Cited by 2,331
Human gut microbiota in obesity and after gastric bypass
Zhang, H., DiBaise, J. K., Zuccolo, A., Kudrna, D., Braidotti, M., Yu, Y., Parameswaran, P., Crowell, M. D., Wing, R., Rittmann, B. E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812600106 · Cited by 1,880
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Inagaki, T., Choi, M., Moschetta, A., Peng, L., Cummins, C. L., McDonald, J. G., Luo, G., Jones, S. A., Goodwin, B., Richardson, J. A., et al. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.09.001 · Cited by 1,865
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819 · cited 1×
“FXR, the central sensor and regulator for the biosynthesis and enterohepatic recycling of bile acids, plays a pivotal role in the control of lipid metabolism (42–45).”
Self-citationBile acids: regulation of synthesis
Chiang, J. Y. L. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900010-jlr200 · Cited by 1,515
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c
渡辺, 光., Houten, S. M., Wang, L., Moschetta, A., Mangelsdorf, D. J., Heyman, R. A., Moore, D. D., & Auwerx, J. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421025 · Cited by 1,397
Differential Adaptation of Human Gut Microbiota to Bariatric Surgery–Induced Weight Loss
Furet, J.-P., Kong, L.-C., Tap, J., Poitou, C., Basdevant, A., Bouillot, J.-L., Mariat, D., Corthier, G., Doré, J., Henegar, C., et al. (2010) · Diabetes · doi:10.2337/db10-0253 · Cited by 1,173
Dumas, M.-E., Barton, R. H., Toye, A., Cloarec, O., Blancher, C., Rothwell, A., Fearnside, J., Tatoud, R., Blanc, V., Lindon, J. C., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601056103 · Cited by 1,042
Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity
Liou, A. P., Paziuk, M., Luevano, J.-M., Machineni, S., Turnbaugh, P. J., & Kaplan, L. M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005687 · Cited by 1,007
Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice
Le Roy, T., Llopis, M., Lepage, P., Bruneau, A., Rabot, S., Bevilacqua, C., Martin, P., Philippe, C., Walker, F., Bado, A., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303816 · Cited by 1,001
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 953
Self-citationFXR is a molecular target for the effects of vertical sleeve gastrectomy
Ryan, K. K., Tremaroli, V., Clemmensen, C., Kovatcheva-Datchary, P., Myronovych, A., Karns, R., Wilson-Pérez, H. E., Sandoval, D. A., Kohli, R., Bäckhed, F., et al. (2014) · Nature · doi:10.1038/nature13135 · Cited by 931
Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · cited 1×
“A phase 2a proof-of-concept trial confirmed that obeticholic acid exerts a hepatoprotective effect on fibrosis (39).”
Farnesoid X receptor is essential for normal glucose homeostasis
Ma, K. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25604 · Cited by 882
Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace
Baffy, G., Brunt, E. M., & Caldwell, S. H. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.10.027 · Cited by 858
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705
Self-citationHolland, W. L., Bikman, B. T., Wang, L.-P., Yuguang, G., Sargent, K. M., Bulchand, S., Knotts, T. A., Shui, G., Clegg, D. J., Wenk, M. R., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43378 · Cited by 705
Rabot, S., Membrez, M., Bruneau, A., Gérard, P., Harach, T., Moser, M., Raymond, F., Mansourian, R., & Chou, C. J. (2010) · The FASEB Journal · doi:10.1096/fj.10.164921 · Cited by 610
Spencer, M. D., Hamp, T. J., Reid, R. W., Fischer, L. M., Zeisel, S. H., & Fodor, A. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2010.11.049 · Cited by 593
Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine
Kim, I., Ahn, S.-H., Inagaki, T., Choi, M., Ito, S., Guo, G. L., Kliewer, S. A., & Gonzalez, F. J. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700330-jlr200 · Cited by 592
Self-citationA Natural Product That Lowers Cholesterol As an Antagonist Ligand for FXR
Urizar, N. L., Liverman, A. B., Dodds, D. T., Silva, F. V., Ordentlich, P., Yan, Y., Gonzalez, F. J., Heyman, R. A., Mangelsdorf, D. J., & Moore, D. D. (2002) · Science · doi:10.1126/science.1072891 · Cited by 549
Self-citationThe Microbiota of the Gut in Preschool Children With Normal and Excessive Body Weight
Karlsson, C. L. J., Önnerfält, J., Xu, J., Molin, G., Ahrné, S., & Thorngren‐Jerneck, K. (2012) · Obesity · doi:10.1038/oby.2012.110 · Cited by 534
Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?
Bhatia, L. S., Curzen, N. P., Calder, P. C., & Byrne, C. D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr453 · Cited by 496
Human cholesterol 7α-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype
Pullinger, C. R., Eng, C. S., Salen, G., Shefer, S., BATTA, A. K., Erickson, S. K., Verhagen, A., Rivera, C. R., Mulvihill, S. J., Malloy, M. J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15387 · Cited by 468
Kong, B., Wang, L., Chiang, J. Y. L., Zhang, Y., Klaassen, C. D., & Guo, G. L. (2012) · Hepatology · doi:10.1002/hep.25740 · Cited by 456
Gut–liver axis: The impact of gut microbiota on non alcoholic fatty liver disease
Compare, D., Coccoli, P., Rocco, A., Nardone, O. M., De Maria, S., Cartenì, M., & Nardone, G. (2012) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2012.02.007 · Cited by 446
Metabolic surgery profoundly influences gut microbial–host metabolic cross-talk
Li, J. V., Ashrafian, H., Bueter, M., Kinross, J., Sands, C., le Roux, C. W., Bloom, S. R., Darzi, A., Athanasiou, T., Marchesi, J. R., et al. (2011) · Gut · doi:10.1136/gut.2010.234708 · Cited by 446
Ceramides as modulators of cellular and whole-body metabolism
Bikman, B. T., & Summers, S. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57144 · Cited by 419
Cipriani, S., Mencarelli, A., Palladino, G., & Fiorucci, S. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m001602 · Cited by 416
Song, K., Li, T., Owsley, E., Strom, S., & Chiang, J. Y. L. (2009) · Hepatology · doi:10.1002/hep.22627 · Cited by 414
Benhamed, F., Denechaud, P.-D., Lemoine, M., Robichon, C., Moldes, M., Bertrand-Michel, J., Ratziu, V., Serfaty, L., Housset, C., Capeau, J., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci41636 · Cited by 408 · cited 2×
“Gut-derived bacterial endotoxin LPS is carried to the liver, where it can activate TLR4 and induce the expression of proinflammatory cytokine genes such as Tnfa and Il6 via activation of the transcription factor NF-kB (33).”
FXR signaling in the enterohepatic system
Matsubara, T., Li, F., & Gonzalez, F. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2012.05.004 · Cited by 381
Self-citationNon-alcoholic fatty liver disease
Sattar, N., Forrest, E., & Preiss, D. (2014) · BMJ · doi:10.1136/bmj.g4596 · Cited by 325
Clinical Utility of Bile Acid Sequestrants in the Treatment of Dyslipidemia: A Scientific Review
Insull, W. (2006) · Southern Medical Journal · doi:10.1097/01.smj.0000208120.73327.db · Cited by 308
Role of ceramides in nonalcoholic fatty liver disease
Pagadala, M., Kasumov, T., McCullough, A. J., Zein, N. N., & Kirwan, J. P. (2012) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2012.04.005 · Cited by 303
Pathways in Microbe-Induced Obesity
Cox, L. M., & Blaser, M. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.05.004 · Cited by 266
Yetukuri, L., Katajamaa, M., Medina-Gomez, G., Seppänen-Laakso, T., Vidal-Puig, A., & Orešič, M. (2007) · BMC Systems Biology · doi:10.1186/1752-0509-1-12 · Cited by 263
Watanabe, M., Horai, Y., Houten, S. M., Morimoto, K., Sugizaki, T., Arita, E., Mataki, C., Sato, H., Tanigawara, Y., Schoonjans, K., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.248203 · Cited by 254
Mitochondrial Ceramide and the Induction of Apoptosis
Siskind, L. J. (2005) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-005-6567-7 · Cited by 253
Gut microbiota and non-alcoholic fatty liver disease: new insights
Aron-Wisnewsky, J., Gaborit, B., Dutour, A., & Clement, K. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12140 · Cited by 248
Cui, J., Huang, L., Zhao, A., Lew, J.-L., Yu, J., Sahoo, S., Meinke, P. T., Royo, I., Peláez, F., & Wright, S. D. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209323200 · Cited by 246
Li, T., Owsley, E., Matozel, M., Hsu, P., Novak, C. M., & Chiang, J. Y. L. (2010) · Hepatology · doi:10.1002/hep.23721 · Cited by 245
Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes
Russo, S. B., Baicu, C. F., Van Laer, A., Geng, T., Kasiganesan, H., Zile, M. R., & Cowart, L. A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci63888 · Cited by 211
The Problem of Establishing Relationships between Hepatic Steatosis and Hepatic Insulin Resistance
Farese, R. V., Zechner, R., Newgard, C. B., & Walther, T. C. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.03.004 · Cited by 209
Ye, D., Li, F. Y. L., Lam, K. S. L., Li, H., Jia, W., Wang, Y., Man, K., Lo, C. M., Li, X., & Xu, A. (2012) · Gut · doi:10.1136/gutjnl-2011-300269 · Cited by 206
Self-citationHirokane, H., Nakahara, M., Tachibana, S., Shimizu, M., & Sato, R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m404255200 · Cited by 189
Zhang, L., Ye, Y., An, Y., Tian, Y., Wang, Y., & Tang, H. (2011) · Journal of Proteome Research · doi:10.1021/pr100792q · Cited by 153
Self-citationHepatic glucose sensing is required to preserve β cell glucose competence
Seyer, P., Vallois, D., Poitry-Yamate, C., Schütz, F., Metref, S., Tarussio, D., Maechler, P., Staels, B., Lanz, B., Grueter, R., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65538 · Cited by 148
Anti-ceramide antibody prevents the radiation gastrointestinal syndrome in mice
Rotolo, J., Stancevic, B., Zhang, J., Hua, G., Fuller, J., Yin, X., Haimovitz-Friedman, A., Kim, K., Qian, M., Cardó-Vila, M., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59920 · Cited by 136
Combined deletion of Fxr and Shp in mice induces Cyp17a1 and results in juvenile onset cholestasis
Anakk, S., Watanabe, M., Ochsner, S. A., McKenna, N. J., Finegold, M. J., & Moore, D. D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42846 · Cited by 129
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts
Krasowski, M. D., Yasuda, K., Hagey, L. R., & Schuetz, E. G. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0427 · Cited by 115 · cited 1×
“…colonized with intestinal bacteria from HFD-treated lines of mice that either developed or did not develop NAFLD had hepatic lipid levels similar to those of the be noted that the relative concentrations of individual bile acids within the bile acid pool differ between mice and humans (40, 41).”
Tissue-specific function of farnesoid X receptor in liver and intestine
Zhu, Y., Li, F., & Guo, G. L. (2011) · Pharmacological Research · doi:10.1016/j.phrs.2010.12.018 · Cited by 100
Self-citationLithocholic acid disrupts phospholipid and sphingolipid homeostasis leading to cholestasis in mice
Matsubara, T., Tanaka, N., Patterson, A. D., Cho, J.-Y., Krausz, K. W., & Gonzalez, F. J. (2011) · Hepatology · doi:10.1002/hep.24193 · Cited by 99
Self-citationAn optimised sample preparation method for NMR-based faecal metabonomic analysis
Wu, J., An, Y., Yao, J., Wang, Y., & Tang, H. (2010) · The Analyst · doi:10.1039/b927543f · Cited by 98
Zeng, H., Liu, J., Jackson, M. I., Zhao, F., Yan, L., & Combs, G. F. (2013) · Journal of Nutrition · doi:10.3945/jn.112.172460 · Cited by 97
Immunolocalization of farnesoid X receptor (FXR) in mouse tissues using tissue microarray
Higashiyama, H., Kinoshita, M., & Asano, S. (2007) · Acta Histochemica · doi:10.1016/j.acthis.2007.08.001 · Cited by 71
Bile Acid-Mediated Control of Liver Triglycerides
Fuchs, C., Claudel, T., & Trauner, M. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358520 · Cited by 68
Houten, S. M., Volle, D. H., Cummins, C. L., Mangelsdorf, D. J., & Auwerx, J. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0113 · Cited by 66
Treatment of Non-Alcoholic Fatty Liver Disease
Dyson, J. K., & Day, C. (2014) · Digestive Diseases · doi:10.1159/000360511 · Cited by 54
Leiss, O., & von Bergmann, K. (1982) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365528209181063 · Cited by 53
Gut Microbiota and Clinical Disease: Obesity and Nonalcoholic Fatty Liver Disease
Park, J. S., Seo, J. H., & Youn, H.-S. (2013) · Pediatric Gastroenterology, Hepatology & Nutrition · doi:10.5223/pghn.2013.16.1.22 · Cited by 49
Matern, S. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80135-3 · Cited by 27
Research works printed but not linked: 1
- 10.1172/jci21025 · DOI · Paper page
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism
Wahlström, A., Sayin, S. I., Marschall, H.-U., & Bäckhed, F. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.05.005 · Cited by 2,851
Diet–microbiota interactions as moderators of human metabolism
Sonnenburg, J. L., & Bäckhed, F. (2016) · Nature · doi:10.1038/nature18846 · Cited by 2,257
The gut-liver axis in liver disease: Pathophysiological basis for therapy
Albillos, A., de Gottardi, A., & Rescigno, M. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.10.003 · Cited by 2,166
Gut microbiota in cardiovascular health and disease
Tang, W. H. W., Kitai, T., & Hazen, S. L. (2017) · Circulation Research · doi:10.1161/circresaha.117.309715 · Cited by 1,670
Metadata
- Authors
- Jiang, C., Xie, C., Li, F., Zhang, L., Nichols, R. G., Krausz, K. W., Cai, J., Qi, Y., Fang, Z.-Z., Takahashi, S., Tanaka, N., Desai, D., Amin, S. G., Albert, I., Patterson, A. D., & Gonzalez, F. J.
- Affiliations
- National Institutes of Health (US)
- Pennsylvania State University (US)
- Corresponding author
- Patterson, Andrew D.
- Gonzalez, Frank J.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-12-15
- Volume
- 125
- Issue
- 1
- Pages
- 386-402
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC4382255
- OpenAlex
- W2124025733
- Cited by
- 693
- References
- 68
- Citations by year
- 2026: 43 · 2025: 52 · 2024: 52 · 2023: 61 · 2022: 76 · 2021: 84 · 2020: 70 · 2019: 63 · 2018: 58 · 2017: 61 · 2016: 46 · 2015: 26
- FWCI
- 33.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Environmental Health Sciences (R01ES022186, ES022186)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- non-alcoholic fatty liver disease, gut microbiota, bile acids, bile acid conjugates, ceramide, ceramide synthesis, SREBP-1c, de novo lipogenesis, hepatic steatosis, high-fat diet, antibiotic therapy, tempol, nuclear receptor signaling, therapeutic target
- MeSH terms
- Receptor, Farnesoid X-Activated, Animals, Anti-Bacterial Agents, Bile Acids and Salts, Cecum, Gene Expression Regulation, Humans, Ileum, Liver, Male, Mice, Inbred C57BL, Mice, Transgenic, Gene Expression, Receptors, Cytoplasmic and Nuclear, Lipid Metabolism, Metabolic Networks and Pathways, Diet, High-Fat, Mitochondrial Dynamics, Microbiota, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.